Spoken Alpha
PALI
PALISADE BIO, INC.
Overview
PALISADE BIO, INC is a Healthcare company operating in Biotechnology with a $328.4M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 9, 2026).
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
No earnings calls indexed for PALI yet
We index calls for roughly 3,000 US-listed companies. If you'd like us to add PALI, reply to your welcome email and we'll prioritize it.
History
Earnings history
- Q2 FY20262026-08-09EPS— vs $-0.05—Rev— vs ——EODHD
- Q1 FY20262026-05-12EPS$-0.05 vs $-0.04-14.5%Rev$0 vs ——EODHD
- Q4 FY20252026-03-24EPS$-0.06 vs $-0.03-97.2%Rev$0 vs ——EODHD
- Q3 FY20252025-11-09EPS$-0.38 vs $-0.55+30.9%Rev$0 vs ——EODHD
- Q2 FY20252025-08-10EPS$-0.58 vs $-0.79+26.6%Rev$0 vs ——EODHD
- Q1 FY20252025-05-11EPS$-0.47 vs $-0.81+42.0%Rev$0 vs ——EODHD
- Q4 FY20242025-03-24EPS$-0.69 vs $-1.99+65.3%Rev$4.0K vs ——EODHD
- Q3 FY20242024-11-06EPS$-2.32 vs $-3.35+30.6%Rev$0 vs ——EODHD
- Q2 FY20242024-08-08EPS$-3.32 vs $-2.93-13.3%Rev$0 vs ——EODHD
- Q1 FY20242024-05-12EPS$-4.59 vs $-4.80+4.4%Rev$0 vs ——EODHD
- Q4 FY20232024-03-25EPS$-6.45 vs $-5.17-24.8%Rev$-250.0K vs ——EODHD
- Q3 FY20232023-11-08EPS$-0.44 vs $-0.39-12.8%Rev$0 vs ——EODHD
- Q2 FY20232023-08-10EPS$-0.53 vs $-0.45-17.8%Rev$0 vs ——EODHD
- Q1 FY20232023-05-10EPS$-0.54 vs $-0.72+25.0%Rev$250.0K vs ——EODHD
- Q4 FY20222023-03-21EPS$6.47 vs $-2.43+100.0%Rev$0 vs ——EODHD
- Q3 FY20222022-11-13EPS$-4.00 vs $-4.000.0%Rev$0 vs ——EODHD
- Q2 FY20222022-08-14EPS$-6.00 vs $-8.50+29.4%Rev$0 vs ——EODHD
- Q1 FY20222022-05-12EPS$-13.00 vs $-14.00+7.1%Rev$0 vs ——EODHD
- Q4 FY20212022-03-16EPS$4.00 vs $-11.75+100.0%Rev$0 vs ——EODHD
- Q3 FY20212021-11-14EPS$21.00 vs $-18.00+100.0%Rev$0 vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-09 | — | $-0.05 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-12 | $-0.05 | $-0.04 | -14.5% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-24 | $-0.06 | $-0.03 | -97.2% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-09 | $-0.38 | $-0.55 | +30.9% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-10 | $-0.58 | $-0.79 | +26.6% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-0.47 | $-0.81 | +42.0% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-24 | $-0.69 | $-1.99 | +65.3% | $4.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-2.32 | $-3.35 | +30.6% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-08 | $-3.32 | $-2.93 | -13.3% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-12 | $-4.59 | $-4.80 | +4.4% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-25 | $-6.45 | $-5.17 | -24.8% | $-250.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-0.44 | $-0.39 | -12.8% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-10 | $-0.53 | $-0.45 | -17.8% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-0.54 | $-0.72 | +25.0% | $250.0K | — | — | EODHD |
| Q4 FY2022 | 2023-03-21 | $6.47 | $-2.43 | +100.0% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-4.00 | $-4.00 | 0.0% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-14 | $-6.00 | $-8.50 | +29.4% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-12 | $-13.00 | $-14.00 | +7.1% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-16 | $4.00 | $-11.75 | +100.0% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-14 | $21.00 | $-18.00 | +100.0% | $0 | — | — | EODHD |
Source: EODHD. PALI reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks PALI's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 90% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $4.77 | $4.32 | +10.5% | -8.6% | -6.8% |
| Q4 FY2026 | $5.03 | $4.49 | +12.1% | -3.8% | -6.7% |
| Q3 FY2026 | $5.12 | $4.54 | +12.7% | -1.4% | -1.2% |
| Q2 FY2026 | $5.04 | $4.39 | +14.7% | -5.1% | -7.6% |
| Q1 FY2025 | $5.39 | $4.56 | +18.2% | +0.4% | -0.9% |
| Q4 FY2025 | $5.08 | $4.52 | +12.5% | -6.5% | -8.9% |
| Q3 FY2025 | $5.35 | $4.48 | +19.5% | -9.4% | -8.5% |
| Q2 FY2025 | $5.59 | $4.73 | +18.2% | -0.4% | -0.2% |
| Q1 FY2024 | $5.18 | $4.63 | +11.9% | -1.1% | -0.6% |
| Q4 FY2024 | $5.49 | $4.67 | +17.6% | -6.7% | -5.6% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- John David FinleyCEO1 yr 5 mono recorded callsCurrentSample
CEO since 2025 • 3/4 beats (75%) • guidance suspended Q3 FY2026
- Mitchell Lawrence JonesChief Medical Officer3 yr 5 mono recorded callsCurrentSample
OTHER_C_SUITE since 2023 • 9/12 beats (75%) • last call held guidance Q1 FY2026
- Thomas HallamCEO1 yr 4 mono recorded callsFormerSample
CEO since 2021 • 8/20 beats (40%) • last guidance cut Q1 FY2026
- Richard J DalyCEO1 yr 2 mono recorded callsFormerSample
CEO since 2016 • 18/40 beats (45%) • last guidance cut Q1 FY2026
- Richard GarrCEO11 mono recorded callsFormerSample
CEO since 2015 • 26/44 beats (59%) • last call held guidance Q3 FY2026
- Jones Jonathan Brian LloydCFO1 yr 10 mono recorded callsFormerSample
CFO since 2015 • 21/44 beats (48%) • guidance suspended Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for PALI.
$ curl https://api.spokenalpha.com/v1/companies/PALIFAQ
Frequently asked about PALI
Where can I find PALISADE BIO, INC.'s (PALI) earnings call transcripts?
Spoken Alpha indexes PALI's earnings call transcripts at https://spokenalpha.com/companies/PALI. Each call links to attributed speakers and parsed analyst Q&A. PALISADE BIO, INC.'s own investor relations page is at https://palisadebio.com/investors-news/.
What sector is PALI in?
PALISADE BIO, INC. (PALI) operates in the Healthcare sector (Biotechnology industry).